TXMD · Nasdaq
Companies at this level ended the following year delisted, bankrupt, restated or silent 13.1% of the time, against 4.0% for companies with a clean record.
Hover or tap a dot to see the filings behind that score.
TherapeuticsMD, Inc. (the “Company”) is unable to file its Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”) without unreasonable effort or expense within the time period prescribed. Due to an inadvertent printer error, the 2025 Form 10-K was filed on March 30, 2026 without the report of the Company’s predecessor independent registered public accounting firm, Berkowitz Pollack Brant, Advisors + CPAs, on the consolidated financial statements as of and for the year ended December 31, 2024. The Company added the report of Berkowitz Pollack Brant, Advisors + CPAs and made certain other printer corrections, including to update hyperlinks. The Company subsequently submitted its 2025 Form 10-K with a filing date of April 1, 2026 within the deadline provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended
NT 10-K, filed 2026-04-01 · auditor
TherapeuticsMD, Inc. (the “Company”) is unable to file its Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”) without unreasonable effort or expense within the time period prescribed. Due to an inadvertent printer error, the 2025 Form 10-K was filed on March 30, 2026 without the report of the Company’s predecessor independent registered public accounting firm, Berkowitz Pollack Brant, Advisors + CPAs, on the consolidated financial statements as of and for the year ended December 31, 2024. The Company added the report of Berkowitz Pollack Brant, Advisors + CPAs and made certain other printer corrections, including to update hyperlinks. The Company subsequently submitted its 2025 Form 10-K with a filing date of April 1, 2026 within the deadline provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended
2026-01-21auditor changed or resigned SEC →
2023-07-10auditor changed or resigned SEC →
TherapeuticsMD, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 to report that it is unable to file its Annual Report on Form 10-K for its fiscal year ended December 31, 2022 (the “2022 Annual Report”) within the prescribed time period without unreasonable effort or expense. The delay is the result of the Company needing additional time to finalize the accounting relating to the Company’s previously announced transaction with Mayne Pharma LLC (the “Mayne Transaction”) and the change in business strategy to become a pharmaceutical royalty company. The closing of the Mayne Transaction was described on the Current Report on Form 8-K filed by the Company on January 3, 2023. The Company anticipates filing the 2022 Annual Report within the prescribed 15-day extension
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice